tradingkey.logo

Oncolytics Biotech Inc <ONC.TO> expected to post a loss of 12 cents a share - Earnings Preview

ReutersMar 5, 2025 1:34 PM
  • Oncolytics Biotech Inc ONC.TO is expected to show no change in quarterly revenue when it reports results on March 7 for the period ending December 31 2024

  • ​LSEG's mean analyst estimate for Oncolytics Biotech Inc is for a loss of 12 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Oncolytics Biotech Inc is C$5.67​, above​ its last closing price of $0.65. ​​​

Previous quarterly performance (using preferred earnings measure in Canadian dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.10

-0.10

-0.12

Missed

-17.8

Jun. 30 2024

-0.10

-0.10

-0.10

Met

0.6

Mar. 31 2024

-0.11

-0.11

-0.09

Beat

16.3​

Dec. 31 2023

-0.15

-0.15

-0.05

Beat

66.1

​​Sep. 30 2023

-0.10

-0.10

-0.14

Missed

-34.6

Jun. 30 2023

-0.11

-0.11

-0.12

Missed

-6.3​

Mar. 31 2023

-0.14

-0.13

-0.10

Beat

24.5

Dec. 31 2022

-0.09

-0.10

-0.15

Missed

-54.7

This summary was machine generated March 5 at 13:34 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI